Investments in progress
We are out there looking for the next big thing or at the office analyzing, verifying the facts, and drafting agreements. Sign up and we will let you know once have found something great.
Our portfolio companies
Our portfolio companies are currently developing diagnostics for early detection of cancer via blood sample, saving lives in emergency care and surgery through software innovations, developing personalised treatments of severe diseases, and much more.
Neogap Therapeutics AB
NEOGAP Therapeutics develops a new type of personalised therapy for the treatment of cancer. The company uses proprietary machine learning algorithms and patented technology to tailor the treatment for each patient and its specific tumour cells.
Encare AB
Encare not only contributes to more cost-effective surgery but also reduces complications and saves lives through their proprietary software solution that helps hospitals implement best practice throughout the entire care chain – from diagnosis and preparation to surgery and rehabilitation.
Capitainer AB
Capitainer offers a unique platform for the self-sampling of fingertip blood and plasma based on a patented microfluidic technology. The products enable easy home sampling with high precision, delivering value across the entire care chain.
Akiram Therapeutics
Akiram has developed a new type of targeted radioimmunotherapy with the potential to become first-in-class. In animal studies, the survival rate has been 100%, and the tumours have been eradicated with just one treatment.
Exits
Former portfolio companies that have reached new heights through acquisition or listing, and continue to thrive under new ownership. These companies continue to make a lasting impact in their respective industries.
Lipigon Pharmaceuticals
Lipigon develops orphan drugs for illnesses due to disorders in how the body handles fat. The company’s major program, Lipsense, focuses on the illness, HoFH, where there is, today, no sufficient treatment.
Read moreInhalation Sciences
Inhalation Science’s technology is used by leading players in the chemical and pharmaceutical sectors to study how airborne particles affect the human body.
Read more